Back to Search
Start Over
Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy
- Source :
- Journal of acquired immune deficiency syndromes (1999). 29(5)
- Publication Year :
- 2002
-
Abstract
- Decreased insulin sensitivity, hyperlipidemia, and body fat changes are considered as risk factors for coronary heart disease (CHD). A clustering of such factors (metabolic syndrome [MSDR]) exponentially increases the risk. Impaired fibrinolysis and increased coagulation are additional independent risk factors for CHD. We studied the effects of protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) on metabolic and hemostatic parameters in 363 HIV-infected individuals, of whom 266 were receiving PI-containing HAART and 97 were treatment naive. The fasting plasma levels of insulin, glucose, triglycerides, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, plasminogen activator inhibitor type I (PAI-1). and fibrinogen were evaluated together with the areas of visceral adipose tissue and the visceral adipose tissue/subcutaneous adipose tissue area ratio. The levels of insulin, triglycerides, cholesterol, and low-density lipoprotein cholesterol; visceral adipose tissue area; low-density lipoprotein/high-density lipoprotein ratio; and visceral adipose tissue/subcutaneous adipose tissue area ratio were significantly increased in patients receiving PI-containing HAART compared with treatment-naive patients. The levels of PAI- 1 and fibrinogen were significantly higher in patients receiving PI-containing HAART. PAI-I levels were higher in individuals with MSDR but also in patients without MSDR who were receiving PI-containing HAART. PAI-I was independently correlated to use of PI-containing HAART, triglyceride level, insulin level, and body mass index (p
- Subjects :
- Adult
Blood Glucose
medicine.medical_specialty
Lipodystrophy
medicine.medical_treatment
Adipose tissue
HIV Infections
chemistry.chemical_compound
Risk Factors
Internal medicine
Antiretroviral Therapy, Highly Active
Fibrinolysis
Plasminogen Activator Inhibitor 1
medicine
Humans
Pharmacology (medical)
business.industry
Cholesterol
Insulin
Fibrinogen
HIV Protease Inhibitors
Middle Aged
medicine.disease
Lipids
Infectious Diseases
Endocrinology
C-Reactive Protein
chemistry
Adipose Tissue
Cardiovascular Diseases
Plasminogen activator inhibitor-1
Immunology
Metabolic syndrome
Insulin Resistance
business
Lipoprotein
Subjects
Details
- ISSN :
- 15254135
- Volume :
- 29
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Journal of acquired immune deficiency syndromes (1999)
- Accession number :
- edsair.doi.dedup.....ccc8ec795ea358506412e8f71ce3c6d7